Tobin Schilke - 30 Jun 2024 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
30 Jun 2024
Net transactions value
+$2,184
Form type
4
Filing time
02 Jul 2024, 17:47:03 UTC
Previous filing
19 Mar 2024
Next filing
03 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Award $2,184 +1,000 +0.52% $2.18 193,666 30 Jun 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2024 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).